You are here

  • Home
  • Online First
  • Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use

Article Text

Article menu

other Versions

Download PDFPDF
Therapeutics
Systematic review and meta-analysis
Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use
  1. Jon O Ebbert
  1. Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Jon O Ebbert, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; ebbert.jon{at}mayo.edu

https://doi.org/10.1136/eb-2013-101462

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013;(5):CD009329.

    Context

    If current trends continue, tobacco use will cause one billion premature deaths globally this century.1 Predominantly in the form of cigarettes, smoking causes 12% of male and 6% female deaths around the world annually.2 Preventing tobacco-related diseases in cigarette smokers commonly requires treatment; and pharmacotherapy is a cornerstone of therapy. Several pharmacotherapies are currently available and others have been evaluated and abandoned. Understanding their comparative efficacies and risks will help guide treatment, policy and future research.

    Methods

    Cahill and colleagues searched the Cochrane Database of Systematic Reviews (CDSR) from inception through to November 2012. Cochrane systematic reviews include only randomised clinical trials. The quality was assessed using standardised methodologies. Network meta-analyses were conducted, which use information across all …

    View Full Text

    Footnotes

    • Competing interests JOE has received research funding support from Pfizer, manufacturer of varenicline and consulting fees from GlaxoSmithKline, manufacturer of nicotine replacement products.

    Linked Articles